ArticleOncogene2010
Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver.
Article in Oncogene, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 60 citations in OpenAlex.
- PIM3 Kinase: A Promising Novel Target in Solid Cancers.Cancers · 2024Review
- Article
- CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells.Cancer gene therapy · 2022Article
- PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.Journal of pediatric surgery · 2021Article
- The kinase polypharmacology landscape of clinical PARP inhibitors.Scientific reports · 2020Article
- The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.Journal of pediatric surgery · 2019Article
- Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.Translational oncology · 2019Article
- Familial association of lung cancer with liver cancer in first-degree relatives.Cancer management and research · 2019Article
- PIM Kinase as an Executional Target in Cancer.Journal of cancer prevention · 2018Review
- Article
- mTORC1 suppresses PIM3 expression via miR-33 encoded by the SREBP loci.Scientific reports · 2017Article
- Ubenimex suppresses Pim-3 kinase expression by targeting CD13 to reverse MDR in HCC cells.Oncotarget · 2017Article
- The role of PIM1/PIM2 kinases in tumors of the male reproductive system.Scientific reports · 2016Article
- Pim-3 is a Critical Risk Factor in Development and Prognosis of Prostate Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Pim Kinase Interacts with Nonstructural 5A Protein and Regulates Hepatitis C Virus Entry.Journal of virology · 2015Article
- Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression.World journal of gastroenterology · 2014Review
- Differential expression of Pim-3, c-Myc, and p-p27 proteins in adenocarcinomas of the gastric cardia and distal stomach.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Genetic Modeling of PIM Proteins in Cancer: Proviral Tagging and Cooperation with Oncogenes, Tumor Suppressor Genes, and Carcinogens.Frontiers in oncology · 2014Review
- The critical role of mRNA destabilizing protein heterogeneous nuclear ribonucleoprotein d in 3' untranslated region-mediated decay of low-density lipoprotein receptor mRNA in liver tissue.Arteriosclerosis, thrombosis, and vascular biology · 2014Article
- CSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia.Blood cancer journal · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pim-3, a proto-oncogene with serine/threonine kinase activity, was enhanced in hepatocellular carcinoma (HCC) tissues. To address the roles of Pim-3 in HCC development, we prepared transgenic mice that express human Pim-3 selectively in liver. The mice were born at a Mendelian ratio, were fertile and did not exhibit any apparent pathological changes in the liver until 1 year after birth. Pim-3-transgenic mouse-derived hepatocytes exhibited accelerated cell cycle progression. The administration of a potent hepatocarcinogen, diethylnitrosamine (DEN), induced accelerated proliferation of liver cells in Pim-3 transgenic mice in the early phase, compared with that observed for wild-type mice. Treatment with DEN induced lipid droplet accumulation with increased proliferating cell numbers 6 months after the treatment. Eventually, wild-type mice developed HCC with a frequency of 40% until 10 month after the treatment. Lipid accumulation was accelerated in Pim-3 transgenic mice with higher proliferating cell numbers, compared with that observed for wild-type mice. Pim-3 transgenic mice developed HCC with a higher incidence (80%) and a heavier burden, together with enhanced intratumoral CD31-positive vascular areas, compared with that observed for wild-type mice. These observations indicate that Pim-3 alone cannot cause, but can accelerate HCC development when induced by a hepatocarcinogen, such as DEN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.